it is shown that the use of 125i-iododeoxyuridine as the target cell label , at the end of the assay , after action of serum and complement , allows the advantages available with this isotopic label to be retained and to avoid the main disadvantage due to its non specific toxicity for the target cells .
C0229671
serum
C0009498
complement